More on FLML

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (10.0 Score)
- Holders
- FDA Archive

Financials

Income Statement
Balance Sheet
Cash Flow Statement

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

FLML Cash Flow Statement

Click line-items for a historical chart and %
Net income (loss) -46.01M
Depreciation and amortization 11.56M
Loss (gain) on disposal of property and equipment 110K
Loss (gain) on sale of marketable securities 666K
Unrealized exchange gain 12K
Grants recognized in research and development expenses and operating income -70K
Remeasurement of related party acquisition-related contingent consideration 52.99M
Remeasurement of related party financing-related contingent consideration 6.14M
Imputed interest on long-term debt
Change in deferred tax and income tax deferred charge -5.68M
Stock-based compensation expense 10.54M
Accounts receivable -7.59M
Inventories 2.08M
Prepaid expenses and other current assets 671K
Research and development tax credit receivable -1.79M
Accounts payable & other current liabilities 1.29M
Deferred revenue -2.2M
Accrued expenses 2.7M
Other long-term assets and liabilities 2.03M
Net cash provided by (used in) operating activities 11.16M
Purchases of property and equipment -1M
Proceeds from disposal of property and equipment
Proceeds from sales of marketable securities 46.48M
Purchase of marketable securities -96.2M
Net cash provided by (used in) investing activities -50.09M
Reimbursment of loans 0
Reimbursment of conditional R&D grants -61K
Proceeds from loans or conditional R&D grants
Principal payments on capital lease obligations
Earn-out payments for related party acquisition-related contingent consideration -6.83M
Royalty payments for related party financing-related contingent consideration -1.12M
Excess tax benefit from stock-based compensation
Cash proceeds from issuance of ordinary shares and warrants 0
Net cash provided by (used in) financing activities -8.01M
Effect of exchange rate changes on cash and cash equivalents 656K
Net increase in cash and cash equivalents -46.28M
Cash and cash equivalents at January 1 65.06M
Cash and cash equivalents at December 31 18.78M
Income tax paid
Interest paid
Income tax paid Grants recognized in research and development expenses and operating income

Entities mentioned with FLML

View All Entities